Indoco Remedies (INDOCO) Q4 24/25 earnings summary

Executive summary

• The year was marked by significant operational challenges, including the launch of Warren Remedies Private Limited (WRPL) for OTC products, major investments in manufacturing upgrades, and a US FDA warning letter impacting the sterile plant in Goa.

• Planned shutdowns for manufacturing upgrades and regulatory issues led to supply disruptions, especially in Europe and the US, severely affecting revenues.

• Despite setbacks, key domestic products like Cyclopam showed strong growth, and digitalization and cost control initiatives are underway.

• Consolidated revenue for Q4 FY25 was ₹3,411 mn, down from ₹4,351 mn in Q4 FY24; full-year revenue was ₹14,948 mn, down from ₹17,620 mn year-over-year.

• The Board recommended a dividend of ₹0.20 per equity share for FY25, subject to shareholder approval.

Financial highlights

• Consolidated Q4 revenues were INR 3,839 million, down from INR 4,391 million year-over-year; full-year consolidated revenues were INR 16,413 million, down from INR 17,882 million.

• Consolidated EBITDA margin for Q4 was -0.2% (-INR 0.8 million), compared to 11.1% (INR 489 million) last year; full-year EBITDA margin was 6% (INR 993 million), down from 13.7% (INR 2,443 million).

• Profit after tax for FY25 was a loss of ₹87 mn, compared to a profit of ₹1,166 mn in FY24.

• API business revenues increased to INR 409 million from INR 217 million year-over-year.

• Standalone net loss for FY25 was ₹87 mn, compared to a net profit of ₹1,166 mn in FY24.

Outlook and guidance

• Incremental sales from the sterile plant are expected to resume in Q2, with gradual recovery in US and European markets anticipated.

• Remediation updates for the US FDA are expected to be completed by July/August, with the site ready for inspection thereafter.

• Management expects improvement in margins and profitability from Q2 onwards as manufacturing normalizes and cost controls take effect.

• Management expressed optimism for future performance, citing several positive triggers for both short and long term.

• Warren Remedies is expected to break even by FY27, with double-digit growth projected for its OTC products.